Oculis Holding AG logo

Oculis Holding AG


Overview | Financials
Company Name Oculis Holding AG
Symbol OCS
Currency USD
Price 11.72
Market Cap 488,724,000
Dividend Yield 0%
52-week-range 9.05 - 14.5
Industry Biotechnology
Sector Healthcare
CEO Dr. Riad Sherif M.B.A., M.D.
Website https://oculis.com

An error occurred while fetching data.

About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is

Related Stocks


Numbers are in millions USD

Numbers are in millions USD